Skip to main content

Safety After Oral Intake

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

MDI Therapeutics
1 program
1
MDI-2517 800mgPhase 11 trial
Active Trials
NCT07220889Recruiting52Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2025
2026
MDI TherapeuticsMDI-2517 800mg

Clinical Trials (1)

Total enrollment: 52 patients across 1 trials

Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants

Start: Nov 2025Est. completion: Jun 202652 patients
Phase 1Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 52 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.